NextCure (NASDAQ:NXTC) Announces Quarterly Earnings Results, Beats Estimates By $1.45 EPS

NextCure (NASDAQ:NXTC) posted its quarterly earnings results on Thursday. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $1.45, FiscalAI reports.

NextCure Trading Down 2.9%

NASDAQ NXTC opened at $12.39 on Friday. The business has a fifty day simple moving average of $12.69 and a 200 day simple moving average of $10.06. NextCure has a 12 month low of $2.69 and a 12 month high of $15.74. The firm has a market capitalization of $43.49 million, a P/E ratio of -0.51 and a beta of 1.50.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Marshall Wace LLP purchased a new stake in NextCure in the 4th quarter valued at about $160,000. Millennium Management LLC bought a new position in shares of NextCure in the fourth quarter valued at approximately $185,000. Geode Capital Management LLC increased its position in shares of NextCure by 18.6% during the fourth quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares during the last quarter. Cable Car Capital LP increased its position in shares of NextCure by 13.1% during the second quarter. Cable Car Capital LP now owns 758,141 shares of the company’s stock valued at $349,000 after acquiring an additional 88,040 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in NextCure by 18.7% during the fourth quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock worth $477,000 after acquiring an additional 5,300 shares during the period. 42.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on NXTC shares. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a research report on Wednesday, January 28th. Wall Street Zen raised NextCure to a “hold” rating in a research note on Saturday, December 13th. Finally, LADENBURG THALM/SH SH upgraded NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Friday, November 7th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.